After Work Seminar with SwedenBIO and Orexo¨
Uppsala, Sweden – October 22, 2018 - Orexo, a specialty pharmaceuticals company, recently won a protracted patent dispute against one of the world’s largest generic drug companies. This dispute took place in the largest pharmaceutical market in the world, the US, where Orexo sells Zubsolv®, a drug combatting opioid dependence. Thanks to a smart and considered IP strategy the successful journey now continues at an increasingly rapid pace.
SwedenBIO and Orexo invite members of SwedenBIO to an educational After Work Seminar in collaboration with Vinge, where you will have the opportunity to share the insights from Orexo’s management and legal counsel from the extensive litigation. In addition to get a brief company update on Orexo and the priorities going forward you will also learn more about the importance of having the right patent protection and get details on the challenges of US patent litigation. You will also enjoy a panel discussion dealing with up to date and essential topics for any life science company acting in the US.
- Nikolaj Sørensen, President and CEO at Orexo
- Stephen McNeeney, Partner and pharmaceutical patent expert at Potter Clarkson LLP
- Errol B. Taylor, Head of Biopharma Patent Litigation at Milbank Tweed Hadley & McCloy LLP
Panel session with the speakers and Robert Rönn, Head of Pharmaceutical Development and IP at Orexo. The panel session is moderated by Wendela Hårdemark and Stojan Arnerstål, IP specialists at Vinge.
Date and time: 8 November 2018 at 5 pm CET
Venue: Vinge, Norrlandsgatan 10, Stockholm, Sweden
Drinks and food will be served. The event expects to end around 7 pm CET. Please register at latest on November 2 at, Registreringslänk 8 nov
For further information do not hesitate to contact:
Orexo, Lena Wange, IR and Communications Manager, +46 (0)18 780 88 00, email@example.com
SwedenBIO, Björn Ursing, Program Director, +46 (0)708 11 12 68, firstname.lastname@example.org
Vinge, Malin Reiman, Legal Assistant, +46 (0)70 429 33 70, email@example.com